Whether this finding could be due to a race-related difference in the tumor’s responsiveness to bevacizumab is deserving of further study to fully evaluate if ANGPT1, ANGPT2, TEK, FGF2, MMP9 and VEGFA are promising targets for future research. This evidence concerns the gene ANGPT2 and neoplasm.